Annuncio pubblicitario
Italia markets open in 8 hours 48 minutes
  • Dow Jones

    39.387,76
    +331,36 (+0,85%)
     
  • Nasdaq

    16.346,26
    +43,46 (+0,27%)
     
  • Nikkei 225

    38.073,98
    -128,42 (-0,34%)
     
  • EUR/USD

    1,0789
    +0,0037 (+0,35%)
     
  • Bitcoin EUR

    58.021,12
    +1.081,52 (+1,90%)
     
  • CMC Crypto 200

    1.343,88
    +43,78 (+3,37%)
     
  • HANG SENG

    18.537,81
    +223,91 (+1,22%)
     
  • S&P 500

    5.214,08
    +26,41 (+0,51%)
     

Vericel to Present at the Morgan Stanley Global Healthcare Conference

Vericel Corporation
Vericel Corporation

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference at 7:30 a.m. ET on Tuesday, September 12, 2023.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leader in advanced therapies for sports medicine and severe burn care. The Company manufactures and markets two cell therapy products and one specialty biologic product in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

ANNUNCIO PUBBLICITARIO

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2023 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact:
Julie Downs
media@vcel.com